Overview
Overview
GHRP-6 (Growth Hormone-Releasing Peptide 6) is a synthetic hexapeptide that functions as a potent growth hormone secretagogue by binding to the ghrelin receptor (GHS-R1a)[1][2]. It stimulates pulsatile GH release from the pituitary gland while maintaining physiological feedback controls, resulting in elevated IGF-1 levels and potential anabolic benefits[3]. This educational protocol presents a three-times-daily subcutaneous approach using practical dilution for precise insulin-syringe measuremen
- Category
- Growth Hormone
- Routes
- subcutaneous
Mechanism
GHRP-6
Mechanism of action
Mechanism of action
GHRP-6 functions as a synthetic ghrelin mimetic by binding to the growth hormone secretagogue receptor (GHS-R1a) in the pituitary gland and hypothalamus [1] [12] . This activation triggers acute, pulsatile growth hormone release from somatotroph cells while simultaneously reducing somatostatin’s inhibitory brake on GH secretion [3] . Unlike continuous GH administration, GHRP-6 maintains physiological feedback controls—as GH and IGF-1 levels rise, endogenous somatostatin increases to prevent excessive elevation, keeping GH pulses within normal physiologic ranges [5] . Beyond its endocrine effects, GHRP-6 exhibits cytoprotective properties through interactions with the CD36 receptor on immune and muscle cells [2] [13] . This secondary pathway activates cell-survival signaling cascades (such as PI3K/Akt) that help protect tissues from oxidative stress and inflammation, explaining many of GHRP-6’s observed tissue-protective benefits in preclinical models including cardioprotection, neuroprotection, and anti-fibrotic effects [2] [14] .
Key research findings
- 01
One of the original synthetic growth hormone-releasing peptides characterized by Bowers and colleagues; a hexapeptide agonist at the ghrelin receptor (GHS-R1a) that stimulates GH release (pharmacology, historical).
- 02
Produces pronounced stimulation of appetite/food intake, consistent with ghrelin-receptor activity (animal model and human study).
- 03
Synergizes with GHRH on GH release in research models because the two act through different receptors (animal and human pharmacology).
- 04
Beyond the GH axis, preclinical studies have explored cytoprotective signaling (e.g., via the CD36 receptor); these remain early-stage and are not established human findings (in vitro / animal model).
Primary source: GH release in humans — well established: Since Bowers' 1984 work, GHRP-6 has been shown to release GH in people, and it was studied as a GH-secretagogue tool for testing pituitary GH reserve. Human studies also confirmed it needs intact GHRH signaling for a maximal pulse, which is why stacks exist. Hormonal footprint — documented: Controlled human comparisons (for example, ghrelin vs GHRP-6 vs GHRP-2) showed GHRP-6 raises GH along with measurable ACTH, cortisol, and prolactin, separating it from the cleaner profile of ipamorelin. Cardioprotection / tissue protection — preclinical: GH secretagogues including GHRP-6 have an animal and cell literature on protecting heart and other tissue from injury. This is early, not approved, and not proven in large human trials. Muscle, fat loss, anti-aging — thin human outcome data: Despite heavy marketing, there is little controlled human evidence that GHRP-6 produces meaningful muscle gain or fat loss on its own. The reliable effects are the GH pulse and the appetite increase.
Pharmacokinetic profile
Single-dose plasma curve over 24h. Shaded band = commonly-cited therapeutic window. Illustrative only.
Researched Effects
Researched benefits
Areas of active research and investigation. Results may vary and are based on preclinical or early clinical data.
Potential Benefits:
Protocol Reference
Protocol reference
Commonly cited research range: 300–900 mcg, daily.
Reference figures reported in the research literature — not a dosing recommendation. For interactive vial math and scheduling, see the Calculator and Schedule tabs.
Cited protocol & reconstitution guide
Source-backed reference fields by phase, including any volume fields authored in the cited guide.
Weeks 1–2
100 mcg
Weeks 3–4
200 mcg
Weeks 5–12
300 mcg
| Phase | Reference amount | Units / volume |
|---|---|---|
| Weeks 1–2 | 100 mcg | 10 units (0.10 mL) |
| Weeks 3–4 | 200 mcg | 20 units (0.20 mL) |
| Weeks 5–12 | 300 mcg | 30 units (0.30 mL) |
Titration protocol
- Weeks 1–2Start100 mcg
3x daily, at least 4 hours apart (commonly morning, midday, and bedtime). Inject on an empty stomach — about 2–3 hours after meals and 30 minutes before eating.
- Weeks 3–4Build200 mcg
3x daily, at least 4 hours apart. Empty-stomach timing: about 2–3 hours after meals and 30 minutes before eating.
- Weeks 5–12Maintenance300 mcg
3x daily, at least 4 hours apart. Empty-stomach timing: about 2–3 hours after meals and 30 minutes before eating.
Storage & Handling
Storage requirements(typical for most peptides)
Can be stored for extended periods. Protect from moisture.
Store in refrigerator door. Never freeze after reconstitution.
Label vials with reconstitution date. Discard if cloudy.
Reconstitution steps
- 01🌡️Let the vial and bacteriostatic water reach room temperature.
- 02🧴Wipe both rubber stoppers with a fresh alcohol swab.
- 03💉Draw 2 mL bacteriostatic water into a sterile syringe — this 2 mg vial yields 1 mg/mL.
- 04💧Aim the water down the inside glass wall, not directly onto the powder.
- 05🔄Do not shake. Swirl gently or let it sit until the powder fully dissolves.
- 06🏷️The solution should look clear and colorless; discard if cloudy or full of particles.
- 07❄️Label with the date and store refrigerated at 2–8 °C (35.6–46.4 °F).
- 08💉Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Additional storage notes
Store at −20 °C (−4 °F) in dry, dark conditions with desiccant if available.
Refrigerate at 2–8 °C (35.6–46.4 °F) and use within 7 days [8] .
Do not refreeze reconstituted solution; prepare aliquots if extended storage is needed.
Allow vials to reach room temperature before opening to minimize condensation.
Clinical Evidence
Clinical evidence
Among the earliest studied GHRPs; research characterizes its GH-releasing and orexigenic (appetite-stimulating) activity.
GH release in humans — well established: Since Bowers' 1984 work, GHRP-6 has been shown to release GH in people, and it was studied as a GH-secretagogue tool for testing pituitary GH reserve. Human studies also confirmed it needs intact GHRH signaling for a maximal pulse, which is why stacks exist. Hormonal footprint — documented: Controlled human comparisons (for example, ghrelin vs GHRP-6 vs GHRP-2) showed GHRP-6 raises GH along with measurable ACTH, cortisol, and prolactin, separating it from the cleaner profile of ipamorelin. Cardioprotection / tissue protection — preclinical: GH secretagogues including GHRP-6 have an animal and cell literature on protecting heart and other tissue from injury. This is early, not approved, and not proven in large human trials. Muscle, fat loss, anti-aging — thin human outcome data: Despite heavy marketing, there is little controlled human evidence that GHRP-6 produces meaningful muscle gain or fat loss on its own. The reliable effects are the GH pulse and the appetite increase.
- 01One of the original synthetic growth hormone-releasing peptides characterized by Bowers and colleagues; a hexapeptide agonist at the ghrelin receptor (GHS-R1a) that stimulates GH release (pharmacology, historical).
- 02Produces pronounced stimulation of appetite/food intake, consistent with ghrelin-receptor activity (animal model and human study).
- 03Synergizes with GHRH on GH release in research models because the two act through different receptors (animal and human pharmacology).
- 04Beyond the GH axis, preclinical studies have explored cytoprotective signaling (e.g., via the CD36 receptor); these remain early-stage and are not established human findings (in vitro / animal model).
Evidence maturity varies by compound; much peptide research is preclinical (in vitro or animal-model). Where human data are limited, findings should be read as research observations, not clinical conclusions.
References
Literature references
Published research articles and sources related to GHRP-6.
- 01European Journal of Endocrinology (1997) — Growth hormone-releasing peptides: comprehensive review of GHRP mechanisms and effects View Sourceet al. (1997)
- 02Clinical Medicine Insights: Cardiology (2017) — Synthetic GHRPs: historical appraisal of cytoprotective effects and mechanisms View Sourceet al. (2017)
- 03Wikipedia — GHRP-6: structure, pharmacology, and mechanism of action overview View Source
- 04European Journal of Pharmaceutical Sciences (2013) — Pharmacokinetic study of GHRP-6 in healthy male volunteers View Sourceet al. (2013)
- 05European Journal of Endocrinology (1997) — Pulsatile GH secretion and feedback mechanisms with GHRPs View Sourceet al. (1997)
- 06Clinical Medicine Insights: Cardiology (2017) — Effect of nutrient intake on GHRP-induced GH release View Sourceet al. (2017)
- 07Sexual Medicine Reviews (2018) — Safety and efficacy of growth hormone secretagogues View Sourceet al. (2018)
- 08Assay Genie Product Datasheet (2021) — GHRP-6 recombinant protein: storage and handling recommendations View Sourceet al. (2021)
- 09CDC (2024) — Preventing unsafe injection practices: basic injection safety guidelines View Sourceet al. (2024)
- 10CDC (2024) — 4 ways to take insulin: injection sites and rotation strategies View Sourceet al. (2024)
- 11Clinical Medicine Insights: Cardiology (2017) — Ghrelin receptor activation and orexigenic effects of GHRP-6 View Sourceet al. (2017)
- 12Wikipedia — GHRP-6 mechanism: ghrelin receptor binding and GH secretagogue activity View Source
- 13Clinical Medicine Insights: Cardiology (2017) — CD36 receptor activation and cell-survival signaling pathways View Sourceet al. (2017)
- 14International Wound Journal (2018) — GHRP-6 prevents cutaneous hypertrophic scarring: proteome study View Sourceet al. (2018)
- 15Sexual Medicine Reviews (2018) — GH secretagogues: effects on lean body mass and fat reduction View Sourceet al. (2018)
- 16Clinical Medicine Insights: Cardiology (2017) — GHRP effects on sleep architecture and slow-wave sleep View Sourceet al. (2017)
- 17Clinical Medicine Insights: Cardiology (2017) — Cardioprotective and neuroprotective effects of GHRPs in preclinical models View Sourceet al. (2017)
- 18Clinical Medicine Insights: Cardiology (2017) — Transient ACTH and cortisol elevation with GHRP-6 administration View Sourceet al. (2017)
- 19Sexual Medicine Reviews (2018) — Safety profile of growth hormone secretagogues in human trials View Sourceet al. (2018)
- 20CDC (2024) — Vaccine administration: subcutaneous injection technique (fact sheet) View Sourceet al. (2024)
- 21CDC (2024) — Vaccine administration: during vaccination best practices View Sourceet al. (2024)
- 22Clinical Diabetes (2019) — The injection technique factor: what you don’t know or teach can make a difference View Sourceet al. (2019)
- 23Pure Lab Peptides — GHRP-6 (2 mg) product page: quality assurance and batch documentation View Source
Observed Effects
Observed effects in cited research
Quality and blood sugar
- Research-use vials are not tested or approved for human use, so purity and contamination are real risks. If you have any blood-sugar condition, GH-raising peptides deserve medical oversight and monitoring.
Research Considerations
Research considerations
Research Use Only - not for human or veterinary therapeutic use. Has been studied in clinical research; on this platform it is handled strictly as a research material. Consult a licensed healthcare professional for any clinical decisions.
- People with diabetes or insulin resistance, since GH can raise blood sugar and lower insulin sensitivity.
- People with active or prior cancer, because GH/IGF-1 signaling is a theoretical concern.
- Pregnant or breastfeeding people (safety not established).
- Competitive athletes, because GH secretagogues are banned and detectable.
Factors noted in the research literature; not patient-specific medical advice.
Regulatory Status
Regulatory status
RUO
Comparisons
Comparisons
| Compound | Mechanism | Route | Status |
|---|---|---|---|
| GHRP-6this | A synthetic hexapeptide GH secretagogue that binds the ghrelin receptor (GHS-R1a) to stimulate pulsatile GH release and appetite via central ghrelin signaling. | subcutaneous | Investigational / RUO |
| HGH 191AA | Recombinant human growth hormone (somatropin), a 191-amino-acid protein identical to endogenous GH, acting on GH receptors to drive IGF-1 production and influence growth, metabolism, and tissue repair. | subcutaneous | Investigational / RUO |
| IGF-1 LR3 | A modified analog of insulin-like growth factor-1 with reduced binding to IGF-binding proteins, giving a markedly extended half-life and prolonged activation of IGF-1 receptor anabolic signaling. | subcutaneous | Investigational / RUO |
| Ipamorelin | Binds to ghrelin receptors to stimulate pituitary gland to release growth hormone. Highly selective with minimal side effects. | subcutaneous | Investigational / RUO |
| Sermorelin | Binds to GHRH receptors to stimulate pulsatile GH release, mimicking natural patterns. Preserves feedback mechanisms. | subcutaneous | Investigational / RUO |
| Glutathione | An endogenous tripeptide (gamma-L-glutamyl-L-cysteinyl-glycine) functioning as a major intracellular antioxidant and redox buffer, supporting phase-II detoxification conjugation and neutralization of reactive oxygen species. | subcutaneous | Investigational / RUO |
| Gonadorelin | A synthetic form of gonadotropin-releasing hormone (GnRH) acting on pituitary GnRH receptors to stimulate luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release, supporting the hypothalamic-pituitary-gonadal axis. | subcutaneous | Investigational / RUO |
Attributes shown for research comparison only; not a statement of efficacy or therapeutic equivalence.
FAQ
Frequently asked questions
GHRP-6 (growth hormone releasing peptide-6) is a synthetic six-amino-acid peptide that activates the ghrelin receptor and signals the pituitary to release a pulse of your own growth hormone. It was the first peptide of its kind, described by Cyril Bowers in 1984, and it is the parent compound behind GHRP-2, hexarelin, and ipamorelin.
In research it is used to study growth hormone release and was used as a tool to test pituitary GH reserve. In the grey market it is used to raise GH for recovery, body composition, and appetite. Its most reliable real-world effects are a short GH pulse and a strong increase in hunger.
Research-use discussions usually describe 100-300 mcg per SubQ injection on an empty stomach, often three times daily and spaced at least 4 hours apart. The common timing pattern is morning, midday, and bedtime. This is educational only, not a dosing recommendation.
Both hit the same receptor, but GHRP-2 releases more GH per microgram and causes less hunger, while GHRP-6 causes the strongest appetite of any peptide in the family and raises cortisol and prolactin a bit more at higher doses. GHRP-2 was approved in Japan as a diagnostic; GHRP-6 is not approved anywhere.
Ipamorelin is usually called the cleaner option because it releases GH without meaningful appetite, cortisol, or prolactin effects. GHRP-6 produces a strong GH pulse but also strong hunger and a broader hormonal footprint. The right choice depends on whether appetite stimulation is wanted or not.
On its own, the evidence for meaningful muscle gain is weak, and the GH rise is modest next to injectable HGH. Any body-composition effect tends to be slow and depends on training, sleep, and nutrition over roughly 8 to 12 weeks. It is most often stacked with a GHRH analog for a larger GH pulse.
The biggest one is intense hunger. Others include water retention, tingling or numbness in the hands, a brief head-rush or flushing, and tiredness. At higher doses it can raise cortisol and prolactin, and because GH affects blood sugar, glucose and insulin sensitivity can shift.
For a common 5 mg vial, adding 3 mL of bacteriostatic water gives about 1,667 mcg/mL, where a 100 mcg dose equals about 0.06 mL or 6 units on a U-100 syringe. Add the water gently down the vial wall, do not shake, and discard if the solution is cloudy.
On an empty stomach, because food, especially fat and carbohydrate, can blunt the GH pulse. Common timing is morning, midday, and bedtime, spaced at least 4 hours apart, with each injection about 2-3 hours after meals and 30 minutes before eating. This is educational only, not a recommendation.
GHRP-6 has no FDA-approved use and no approved drug product in major regulated markets. It is sold as research-use-only material rather than as a medicine. It is also prohibited in sport by WADA at all times. Confirm current rules before relying on this.
No. This is an educational research reference, not medical advice or a treatment plan. Always talk to a qualified clinician before considering any peptide.
Research-use notice
Research Use Only. This educational content and calculation support is intended for private research documentation. It does not provide medical advice, human-use directions, or claims of safety or effectiveness.